Key result
TAVI achieves 100% device success in patients with pre-existing mechanical mitral valve replacement.
Why the study?
Treatment of patients with pre-existing mechanical mitral valve replacement undergoing TAVI is challenging due to possible interference between the TAVI prosthesis and the mitral valve.
Is transcatheter aortic valve implantation (TAVI) safe and feasible in patients with pre-existing mechanical mitral valve prostheses?
Observational (n=16)
No
Is transcatheter aortic valve implantation (TAVI) safe and feasible in patients with pre-existing mechanical mitral valve prostheses?
TAVI in patients with pre-existing mechanical mitral valves is feasible but carries significant risks of major complications, including interference with the mitral prosthesis.
TAVI in mechanical MVR patients shows high periprocedural risks; small cohort leaves optimal device selection and technique open.
OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has become standard therapy for aortic stenosis patients with intermediate or high operative risk. Treatment of patients with pre-existing mechanical mitral valve replacement (MVR) is challenging due to possible interference between the TAVI prosthesis and MVR. We present our single-center experience with this special patient cohort. METHODS: A total of 1960 patients underwent TAVI at our institution between 2009 and March 2018; of these, 16 patients had pre-existing mechanical MVR. Device success and adverse events were analyzed according to the Valve Academic Research Consortium (VARC)-2 criteria. Patients were followed for at least 12 months. RESULTS: Mean patient age was 81.5 ± 4.4 years. The patients had a mean logistic EuroScore of 37.1 ± 13.5% and STS score of 7.1 ± 3.2%. Successful valve deployment was achieved in all patients, peri-interventional stroke rate was 0.0%, and permanent pacemaker was implanted in 2 patients (12.5%). Two patients experienced major complications, with blockage of the MVR disc in 1 patient and annulus rupture in 1 patient. Hence, 30-day mortality was 12.5% and 1-year mortality was 25.0%. CONCLUSION: TAVI in patients with mechanical MVR is challenging and requires careful preparation and choice of TAVI device. Repositionable and retrievable devices seem to be a safer option.
No takes yet. Share an insight, caveat, or question.
Scholtz et al. (2019) conducted an observational in Aortic stenosis with pre-existing mechanical mitral valve replacement (n=16). Transcatheter aortic valve implantation (TAVI) was evaluated on Device success and adverse events (VARC-2 criteria). Transcatheter aortic valve implantation in patients with pre-existing mechanical mitral valve replacement achieved 100% device success, with 12.5% 30-day and 25.0% 1-year mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: